Finnish CRC | Australian CRC | Finnish EC | ||||
---|---|---|---|---|---|---|
Sporadic MSS | Sporadic MSI | Lynch | Sporadic MSS | Sporadic MSI | Lynch | |
Total number of tumors | 47 | 40 | 28 | 52 | 38 | 36 |
Gender | ||||||
Female | 27 | 27 | 12 | 25 | 20 | 36 |
Male | 20 | 13 | 16 | 27 | 18 | - |
Mean age of diagnosis (years) | 69.9 | 72.8 | 43.6 | 67.6 | 67.1 | 50.2 |
Germline mutation present in MMR genes (total) | N/A | N/A | 28 | N/A | N/A | 36 |
MLH1 | 28 | 30 | ||||
MSH2 | 0 | 3 | ||||
MSH6 | 0 | 3 | ||||
MMR statusa | ||||||
Deficient | 0 | 40 | 28 | 0 | 38 | 36 |
Proficient | 47 | 0 | 0 | 52 | 0 | 0 |
Tumor grade | ||||||
1 | 13/21 | 5/14 | 5/16 | 1/52 | 0/36 | 14/29 |
2 | 5/21 | 6/14 | 6/16 | 46/52 | 24/36 | 9/29 |
3 | 3/21 | 3/14 | 5/16 | 5/52 | 12/36 | 6/29 |
Tumor stage (Dukes/WHO/FIGO)b | ||||||
A/I/I | 7/46 | 2/37 | 5/19 | 8/52 | 3/38 | 12/22 |
B/II/II | 16/46 | 24/37 | 10/19 | 24/52 | 20/38 | 7/22 |
C/III/III | 16/46 | 8/37 | 4/19 | 17/52 | 13/38 | 1/22 |
D/IV/IV | 7/46 | 3/37 | 0/19 | 3/52 | 2/38 | 3/22 |
Location of CRCc | ||||||
Proximal | 20/44 | 34/39 | 22/27 | 20/52 | 27/38 | - |
Distal | 24/44 | 5/39 | 5/27 | 32/52 | 11/38 | - |